102 related articles for article (PubMed ID: 31892551)
1. High Expression of
Motomura H; Nozaki Y; Onaga C; Ozaki A; Tamori S; Shiina TA; Kanai S; Ohira C; Hara Y; Harada Y; Takasawa R; Hanawa T; Tanuma SI; Mano Y; Sato T; Sato K; Akimoto K
Anticancer Res; 2020 Jan; 40(1):35-52. PubMed ID: 31892551
[TBL] [Abstract][Full Text] [Related]
2. High PKCλ expression is required for ALDH1-positive cancer stem cell function and indicates a poor clinical outcome in late-stage breast cancer patients.
Nozaki Y; Motomura H; Tamori S; Kimura Y; Onaga C; Kanai S; Ishihara Y; Ozaki A; Hara Y; Harada Y; Mano Y; Sato T; Sato K; Sasaki K; Ishiguro H; Ohno S; Akimoto K
PLoS One; 2020; 15(7):e0235747. PubMed ID: 32658903
[TBL] [Abstract][Full Text] [Related]
3. GLO 1 and PKCλ Regulate ALDH1-positive Breast Cancer Stem Cell Survival.
Motomura H; Tamori S; Yatani MA; Namiki A; Onaga C; Ozaki A; Takasawa R; Mano Y; Sato T; Hara Y; Sato K; Xiong Y; Harada Y; Hanawa T; Tanuma SI; Sasaki K; Ohno S; Akimoto K
Anticancer Res; 2021 Dec; 41(12):5959-5971. PubMed ID: 34848450
[TBL] [Abstract][Full Text] [Related]
4. Correlation between c-Met and ALDH1 contributes to the survival and tumor-sphere formation of ALDH1 positive breast cancer stem cells and predicts poor clinical outcome in breast cancer.
Nozaki Y; Tamori S; Inada M; Katayama R; Nakane H; Minamishima O; Onodera Y; Abe M; Shiina S; Tamura K; Kodama D; Sato K; Hara Y; Abe R; Takasawa R; Yoshimori A; Shinomiya N; Tanuma SI; Akimoto K
Genes Cancer; 2017 Jul; 8(7-8):628-639. PubMed ID: 28966724
[TBL] [Abstract][Full Text] [Related]
5. High expression of PKCλ and ALDH1A3 indicates a poor prognosis, and PKCλ is required for the asymmetric cell division of ALDH1A3-positive cancer stem cells in PDAC.
Kasai T; Tamori S; Takasaki Y; Matsuoka I; Ozaki A; Matsuda C; Harada Y; Sasaki K; Ohno S; Akimoto K
Biochem Biophys Res Commun; 2023 Aug; 669():85-94. PubMed ID: 37267864
[TBL] [Abstract][Full Text] [Related]
6. Luminal B Breast Cancer Coexpressing
Ozaki A; Matsuda A; Maemura Y; Tada Y; Kasai T; Nagashima Y; Onaga C; Hara Y; Kitabatake K; Tsukimoto M; Tamori S; Sasaki K; Ohno S; Akimoto K
Anticancer Res; 2024 Jan; 44(1):37-47. PubMed ID: 38160009
[TBL] [Abstract][Full Text] [Related]
7. ALDH(+)/CD44(+) cells in breast cancer are associated with worse prognosis and poor clinical outcome.
Qiu Y; Pu T; Guo P; Wei B; Zhang Z; Zhang H; Zhong X; Zheng H; Chen L; Bu H; Ye F
Exp Mol Pathol; 2016 Feb; 100(1):145-50. PubMed ID: 26687806
[TBL] [Abstract][Full Text] [Related]
8. ALDH1A3, the Major Aldehyde Dehydrogenase Isoform in Human Cholangiocarcinoma Cells, Affects Prognosis and Gemcitabine Resistance in Cholangiocarcinoma Patients.
Chen MH; Weng JJ; Cheng CT; Wu RC; Huang SC; Wu CE; Chung YH; Liu CY; Chang MH; Chen MH; Chiang KC; Yeh TS; Su Y; Yeh CN
Clin Cancer Res; 2016 Aug; 22(16):4225-35. PubMed ID: 27076629
[TBL] [Abstract][Full Text] [Related]
9. High
Onaga C; Tamori S; Motomura H; Ozaki A; Matsuda C; Matsuoka I; Fujita T; Nozaki Y; Hara Y; Kawano Y; Harada Y; Sato T; Mano Y; Sato K; Akimoto K
Anticancer Res; 2021 Jan; 41(1):43-54. PubMed ID: 33419798
[TBL] [Abstract][Full Text] [Related]
10. Differential Functional Roles of ALDH1A1 and ALDH1A3 in Mediating Metastatic Behavior and Therapy Resistance of Human Breast Cancer Cells.
Croker AK; Rodriguez-Torres M; Xia Y; Pardhan S; Leong HS; Lewis JD; Allan AL
Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28937653
[TBL] [Abstract][Full Text] [Related]
11. High Expression of
Ozaki A; Motomura H; Tamori S; Onaga C; Nagashima Y; Kotori M; Matsuda C; Matsuda A; Mochizuki N; Sato T; Hara Y; Sato K; Miyagi Y; Nagashima Y; Hanawa T; Harada Y; Xiong Y; Sasaki K; Ohno S; Akimoto K
Anticancer Res; 2022 Jul; 42(7):3299-3312. PubMed ID: 35790283
[TBL] [Abstract][Full Text] [Related]
12. Aldehyde dehydrogenase 1A3 influences breast cancer progression via differential retinoic acid signaling.
Marcato P; Dean CA; Liu RZ; Coyle KM; Bydoun M; Wallace M; Clements D; Turner C; Mathenge EG; Gujar SA; Giacomantonio CA; Mackey JR; Godbout R; Lee PW
Mol Oncol; 2015 Jan; 9(1):17-31. PubMed ID: 25106087
[TBL] [Abstract][Full Text] [Related]
13. Functional consequence of the MET-T1010I polymorphism in breast cancer.
Liu S; Meric-Bernstam F; Parinyanitikul N; Wang B; Eterovic AK; Zheng X; Gagea M; Chavez-MacGregor M; Ueno NT; Lei X; Zhou W; Nair L; Tripathy D; Brown PH; Hortobagyi GN; Chen K; Mendelsohn J; Mills GB; Gonzalez-Angulo AM
Oncotarget; 2015 Feb; 6(5):2604-14. PubMed ID: 25605252
[TBL] [Abstract][Full Text] [Related]
14. Glyoxalase 1 and protein kinase Cλ as potential therapeutic targets for late-stage breast cancer.
Motomura H; Ozaki A; Tamori S; Onaga C; Nozaki Y; Waki Y; Takasawa R; Yoshizawa K; Mano Y; Sato T; Sasaki K; Ishiguro H; Miyagi Y; Nagashima Y; Yamamoto K; Sato K; Hanawa T; Tanuma SI; Ohno S; Akimoto K
Oncol Lett; 2021 Jul; 22(1):547. PubMed ID: 34093768
[TBL] [Abstract][Full Text] [Related]
15. Expression of S100A4 and Met: potential predictors for metastasis and survival in early-stage breast cancer.
Lee WY; Su WC; Lin PW; Guo HR; Chang TW; Chen HH
Oncology; 2004; 66(6):429-38. PubMed ID: 15452371
[TBL] [Abstract][Full Text] [Related]
16. Lnc RNA H19 is associated with poor prognosis in breast cancer patients and promotes cancer stemness.
Shima H; Kida K; Adachi S; Yamada A; Sugae S; Narui K; Miyagi Y; Nishi M; Ryo A; Murata S; Taniguchi H; Ichikawa Y; Ishikawa T; Endo I
Breast Cancer Res Treat; 2018 Aug; 170(3):507-516. PubMed ID: 29693231
[TBL] [Abstract][Full Text] [Related]
17. ALDH1A1 mRNA expression in association with prognosis of triple-negative breast cancer.
Liu Y; Baglia M; Zheng Y; Blot W; Bao PP; Cai H; Nechuta S; Zheng W; Cai Q; Shu XO
Oncotarget; 2015 Dec; 6(38):41360-9. PubMed ID: 26462023
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological implications of Tiam1 overexpression in invasive ductal carcinoma of the breast.
Li Z; Liu Q; Piao J; Hua F; Wang J; Jin G; Lin Z; Zhang Y
BMC Cancer; 2016 Aug; 16(1):681. PubMed ID: 27562113
[TBL] [Abstract][Full Text] [Related]
19. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
[TBL] [Abstract][Full Text] [Related]
20. miR-340 inhibition of breast cancer cell migration and invasion through targeting of oncoprotein c-Met.
Wu ZS; Wu Q; Wang CQ; Wang XN; Huang J; Zhao JJ; Mao SS; Zhang GH; Xu XC; Zhang N
Cancer; 2011 Jul; 117(13):2842-52. PubMed ID: 21692045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
